Company Description
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
The company’s lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.
Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions.
IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026.
The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2012 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 38 |
| CEO | Brigette Roberts |
Contact Details
Address: 101 College Street, Suite 210 New Haven, Connecticut 06510 United States | |
| Website | irulya.com |
Stock Details
| Ticker Symbol | IRLA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001662774 |
| CUSIP Number | 22053A305 |
| ISIN Number | US22053A3059 |
| Employer ID | 90-1024039 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Brigette Roberts M.D. | Chief Executive Officer, Principal Executive Officer and Director |
| Dr. Keith R. Fandrick Ph.D. | Chief Operating Officer |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2026 | 144 | Filing |
| Oct 19, 2026 | 8-K | Current Report |
| Oct 14, 2026 | SCHEDULE 13G | Filing |
| Oct 14, 2026 | SCHEDULE 13G | Filing |
| Oct 9, 2026 | 8-K | Current Report |
| Oct 8, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 6, 2026 | 8-K | Current Report |
| Oct 2, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Oct 2, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 8-K | Current Report |